Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Cervomed Inc (CRVO)

Cervomed Inc (CRVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization GlobeNewswire - Tue Jun 10, 7:00AM CDT

CRVO : 6.81 (+4.45%)
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates GlobeNewswire - Mon May 12, 7:00AM CDT

CRVO : 6.81 (+4.45%)
CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference GlobeNewswire - Wed May 7, 7:00AM CDT

CRVO : 6.81 (+4.45%)
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025 GlobeNewswire - Wed Apr 2, 6:00AM CDT

CRVO : 6.81 (+4.45%)
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™) GlobeNewswire - Tue Mar 25, 7:00AM CDT

CRVO : 6.81 (+4.45%)
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates GlobeNewswire - Mon Mar 17, 7:00AM CDT

CRVO : 6.81 (+4.45%)
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies GlobeNewswire - Mon Mar 10, 3:05PM CDT

CRVO : 6.81 (+4.45%)
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference GlobeNewswire - Fri Jan 31, 7:00AM CST

CRVO : 6.81 (+4.45%)
CervoMed to Present at the 8th International Lewy Body Dementia Conference GlobeNewswire - Wed Jan 29, 7:00AM CST

CRVO : 6.81 (+4.45%)
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Thu Dec 12, 2024

CRVO : 6.81 (+4.45%)

Barchart Exclusives

Teladoc Stock Is a ‘Coiled Spring’ That Could Surge Higher. Should You Buy TDOC Here? Barchart - Tue Jun 24, 3:43PM CDT
Teladoc stock gains as Citron Research posts a bullish report in its favor. Wall Street remains positive on TDOC shares for the second half of 2025 as well. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot